Indication
Recurrent T Acute Lymphoblastic Leukemia
5 clinical trials
20 products
8 drugs
Clinical trial
A Phase II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase 1 Trial to Evaluate the Safety of Single Agent Flotetuzumab in Advanced CD123-Positive Hematological MalignanciesStatus: Active (not recruiting), Estimated PCD: 2026-05-05
Product
DexamethasoneProduct
DiphenhydramineProduct
FlotetuzumabProduct
IbuprofenProduct
RanitidineClinical trial
Phase I/II Study of the Combination of Low-Intensity Chemotherapy and Venetoclax (ABT-199) in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)Status: Active (not recruiting), Estimated PCD: 2026-12-31
Drug
cyclophosphamideProduct
CytarabineProduct
MethotrexateProduct
NelarabineProduct
PegaspargaseProduct
PrednisoneDrug
VarlilumabProduct
VenetoclaxDrug
VincristineProduct
AcetaminophenClinical trial
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory LeukemiaStatus: Withdrawn, Estimated PCD: 2023-09-01
Drug
fludarabineDrug
DocetaxelDrug
R-CHOPClinical trial
Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL)Status: Recruiting, Estimated PCD: 2025-07-01
Product
PegfilgrastimProduct
Anti-CD123 ADC IMGN632Drug
FilgrastimDrug
mFOLFOX6Product
MercaptopurineProduct
MesnaProduct
Tagraxofusp-erzs